Catalyst Wire Dossier Catalyst Wire Dossier

Skyrizi (risankizumab)

risankizumab · AbbVie
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Skyrizi (risankizumab), covering 2026-03-16 to 2026-03-16. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab [Phase 3]

See pricing